Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MAR-DILTIAZEM CD - Health Canada Drug Approval Details

Approvals/Health Canada/MAR-DILTIAZEM CD

Authorized

STANDARD

MAR-DILTIAZEM CD

MARCAN PHARMACEUTICALS INC🇨🇦 Health Canada

Approval Date: Apr 6, 2026
Approval ID: 559f881110a97620
Company: MARCAN PHARMACEUTICALS INC
Type: Standard

Approval Details

Approval Id: 559f881110a97620
Drug Approval Canada Name: MAR-DILTIAZEM CD
Product Name: MAR-DILTIAZEM CD
Status: Marketed
Status Date: 2020-03-30
Original Market Date: 2020-03-30
Drug Class: Human
Dosage Form: Capsule (Controlled-Delivery)
Route Of Administration: Oral
Schedule: PRESCRIPTION
Ahfs: 24:28.92
Atc Original: C08DB01 DILTIAZEM
Aig Number: 0115863008
Company Name: MARCAN PHARMACEUTICALS INC
Company Address: 2 Gurdwara Rd., Suite 400 Ottawa Ontario Canada K2E 1A2

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Apr 6, 2026

Approval ID

559f881110a97620

Type

Standard

Back to Health Canada Approvals